PR87233

TAIPEI, Dec. 16, 2020 /PRNewswire=KYODO JBN/ --

APRINOIA Therapeutics Inc. today announced that they had executed a worldwide

non-exclusive licensing agreement for Biogen Inc. (Nasdaq: BIIB) to access

APRINOIA's positron emission tomography (PET) imaging tracer, [18F]-APN-1607,

for neurodegenerative diseases. This is an extension of a collaboration between

APRINOIA and Biogen to discover novel PET imaging tracers for visualization and

quantification of abnormal tau protein accumulation in the brain.

18F-APN-1607 is a new generation tau PET imaging tracer with improved

selectivity and off-target binding profiles. It is designed to specifically

recognize tau proteins in their pathological aggregated states. Pathological

tau proteins are associated with neurodegeneration in Alzheimer's disease (AD)

and other tau-related brain disorders (tauopathies), including progressive

supranuclear palsy (PSP), frontotemporal dementia (FTD), chronic traumatic

encephalopathy (CTE), and corticobasal degeneration (CBD). [18F]-APN-1607 could

be used to quantify tau burden and visualize distribution of tau abnormality in

different types of tauopathies, offering broad clinical utilities.

"We are excited to announce our collaboration with Biogen. It has been a

fruitful collaboration to combine expertise from both companies to advance our

understanding of [18F]-APN-1607 and to discover next generation imaging

tracers," said Ming-Kuei Jang, CEO of APRINOIA. "APRINOIA is committed to make

[18F]-APN-1607 and our other imaging tools available to research and medical

communities to explore clinical utilities of those tools and facilitate

clinical research of potential treatments for neurodegenerative diseases."

About APRINOIA

APRINOIA Therapeutics is currently advancing a pipeline featuring diagnostic

and therapeutic programs, collectively targeting brain disorders associated

with abnormal accumulation of pathological proteins, including tau and

alpha-synuclein, from its proprietary small molecule and antibody discovery

platforms. APRINOIA is committed to building a pipeline of innovative products,

as well as developing partnership with global and regional pharmaceutical

companies to accelerate its programs. The company currently has operations in

Taipei, Suzhou, Shanghai, Tokyo, and Boston.

Contact: Ms. Mingwei Pu, Email: mingwei.pu@aprinoia.com    

SOURCE: APRINOIA Therapeutics